By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang ...

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 ...

Moderna’s stock climbed in after-hours trading while shares of Arbutus fell.

A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...

Investors who closely watch the healthcare sector are keeping an eye on Moderna (NASDAQ:MRNA) as its shares are up 12% over ...

The settlement, which requires Moderna to pay the plaintiffs $950 million upfront plus up to $1.3 billion in contingent commitments, is an outcome “better than feared,” according to analysts.

Moderna Inc. agreed to pay $950 million to settle litigation related to the delivery technology behind its Covid shot, ...

Announced days before a trial, the deal settles a longstanding dispute and avoids what one analyst called a “worst-case scenario” financially for Moderna.